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Introduction!
!
Few other public health issues can match the tax on society that cancer has 
placed. Contributing to this are inadequate treatments with low efficiency and 
large number of negative side effects. Therefore, it is necessary to develop a 
highly efficient low toxic cure for cancer. Cancer drug candidate SHetA2, which 
was developed by scientists at OSU and OUHSC, has shown promising results: 
it is capable of inhibiting the growth of all cancer cell lines in the National 
Cancer Institute without toxic side effects in animal tests[1]. Phase 0 clinical 
tests are currently being conducted at OUHSC for ovarian cancer prevention. 
The application of SHetA2 as a cure, however, is limited by its low efficiency, 
only killing about 80% of cancer cells and leaving the rest to continue cancerous 
growth. Therefore, the creation of SHetA2 analogs[2] with increased efficiency 















1.  Mortalin sequesters the 
apoptotic regulator protein p53 
in the cytoplasm preventing 
apoptosis.  
2.  The SHetA2 molecule binds to 
mortalin and prevents formation 
of the complex. The displaced 
p53 protein is free to migrate to 
the nucleus and induce 
apoptosis[3].   
Apoptotic Cell 
Full Length Mortalin 
NMR Spectroscopy!










The data presented here will help guide the development of the next generation of 
SHetA2 derived analogs to further its potential as a cancer treatment.!
!
HSQC spectra and shifted peaks. Subjecting analogs 
to NMR study allows identification of the amino acids 
that are critically involved with binding. In the HSQC 
spectra, peaks correspond to each amino acid residue of 
mortalin. Peak shift observed following titration with 
SHetA2 indicates perturbation of that amino acid. 
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 S473_CO_Lig_NH       62.46% 52.97% 8.44% 0.367% 51% 
S473_CO_Lig_N1H1       0.00% 82.88% 37.12% 0.00% 2.14% 
T474_CO_Lig_NH       0.00% 0.095% 0.00% 81.83% 30.06% 
T474_CO_Lig_N1H       0.00% 0.00% 0.00% 94.33% 92.76% 
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Comparison of SHetA2 and analogs 
at lowest binding energy during 50 
ns GROMACS simulation. 
Hydrogen bonding is indicated with 
dotted lines, amino acids with large 
contributions are shaded red. Above: 
Effect of increased hydrophobicity in 
ring A due to added geminal diethyl 
groups (6B).  Right: Comparison of 
thiourea (2A) and urea linkers (3A). 
Data for hydrogen bonding is 
summarized in the table. 
SHetA2 Analog 5A Analog 6B 
•  -167.9 kJ/mol •  -192.3 kJ/mol •  -148.6 kJ/mol 









Summary of hydrogen bonding during 50 ns simulation. Percentage indicates the 
amount of time during simulation that hydrogen bond was formed. Note the 
improved performance of with increased hydrophobicity (6B), and the urea linker 
(3A). This data is in agreement with the biological information. 
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